Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Goodfellow Gems #62
Goodfellow Gems #62
Wednesday 16 August 2017, 12:01 PM
Most antidepressant benefit seen in primary care is due to placebo. Talk first prescribe later.
An update to a Cochrane review on antidepressants in primary care found that the most of the benefit was due to the placebo.1
For tricyclics, 63% o
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
1. Arroll et al. Antidepressants for treatment of depression in primary care. A systematic review and meta-analysis. 2016 http://www.publish.csiro.au/HC/pdf/HC16008
2. Fournier et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010. https://www.ncbi.nlm.nih.gov/pubmed/20051569
3. Depression in adults: recognition and management. NICE Guidance (CG90). https://www.nice.org.uk/guidance/cg90